Heparin and Aspirin in Pregnant Sudanese women with Recurrent Miscarriage Associa-ted with Antiphospholipid Antibodies
), Elsir A. Elussein(2), Maha M. Omer(3), Samaan I. Samaan(4), Fawzi A/Rahim(5), Ishag Adam(6),
(1)
(2)
(3)
(4)
(5)
(6)
Corresponding Author
Abstract
This was a prospective clinical trial conducted at Khartoum Fertility Center, during the period June 2002 to February 2005 to investigate the efficacy of unfractionated heparin and low-dose aspirin as prophylaxis against pregnancy loss in 58 pregnant Sudanese women with recurrent (>3) miscarriages associated with antiphospholipid syndrome (APS).
Three (5.1%) patients had early miscarriages, three (5.1%) patients developed pre-eclamptic toxaemia and forty-seven (81%) of the 58 patients had cesarean delivery. Forty-seven (81%) women had live births and 8(13.8%) had preterm deliveries. Eight (13.8%) of the neonates were admitted to the intensive care unit for various reasons. There were 6(10.3%) perinatal deaths, all of them were due to prematurity. None of the patients developed thromboembolic episode. There was no maternal death.
The rate of live birth in this study was consistent with the previous reports. This was a none controlled study; thus controlled clinical trials using low molecular weight heparin are urgently needed. (Afr J Reprod Health 2007; 11[2]:).
Keywords: miscarriage, pregnancy, heparin, aspirin, Sudan
References
Pattison NS, Chamley LW, Liggins GC, Butler WS. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993; 100: 909-913.
Ahmed AA, Ortashi OM, Abdelmagied AH, Ramzi MS. Risk factors for recurrent miscarriage in Sudanese women. Saudi Med J 2004; 25:1295-1297.
Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183:1008-1012.
Hanly JG. Antiphospholipid syndrome: an overview. CMAJ 2003; 24: 168: 1675-1682.
Nishiguchi T, Kobayashi T. Antiphospholipid syndrome: characteristics and obstetrical management. Curr Drug Targets. 2005; 6: 593-605.
Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril 2005; 83: 684-690.
Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (orantiphospholipid antibodies). BMJ 1997; 25: 253-257.
Franklin RD, Kutteh WH. Effects of unfrac--tionated and low molecular weight heparin on antiphospholipid antibody binding in vitro.Obstet Gynecol 2003; 101: 455-462.
Ruffatti A, Favaro M, Tonello M, De Silvestro G, Pengo V, Fais G, Suma V, Chiarelli S, Todesco S. Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. Lupus 2005; 14:120-128.
Kutteh WH: Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996; 174:1584-1589.
Farguharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: A randomized, controlled clinical trial of treatment. Obstet Gynecol 2002; 100: 408-413.
Brigham S, Conlon C, Farguharson RG: A longitudinal study of pregnancy outcome following idiopathic recurring miscarriage. Hum Reprod 1999; 14: 2868-2871.
Liddell H S, Patisson NS, Zanderigo A. Recurrent miscarriage: outcome after supportive care in early pregnancy. Aust N ZJ obstet Gynacol 1991; 31: 320-322.
Rai RS, Clifford K., Cohen H. Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Repord 1995; 10: 3301-3304.
Ruffatti A, Favaro M, Tonello M, De Silvestro G, Pengo V, Fais G, Suma V, Chiarelli S, Todesco S. Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. Lupus 2005, 14:120-128.
Stone S, Hunt BJ, Seed PT, Parmar K, Khamashta MA, Poston. Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy. Am J Obstet Gynecol 2003; 188:454
Article Metrics
Abstract View
: 453 times
Download : 198 times
Refbacks
- There are currently no refbacks.
